News >

Novel Therapeutics, Dosing Strategies Offer Hope in Metastatic Pancreatic Cancer

Caroline Seymour
Published: Thursday, Mar 14, 2019

Shubham Pant, MD

Shubham Pant, MD
Given the poor prognosis of pancreatic cancer and the steady stream of negative phase III trials, clinicians are facing an uphill battle in the treatment of this patient population.

“There is nothing known as early pancreatic cancer; it’s truly a metastatic disease with a dire prognosis in which as many patients die of [their cancer] as those who get diagnosed every year,” said Shubham Pant, MD, in a presentation during the 2019 OncLive® State of the Science Summit™ on Gastrointestinal Cancers.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication